BR9612203A - Amidas tricíclicas úteis para a inibição da função da g-pro-teína e para o tratamento de doenças proliferativas - Google Patents

Amidas tricíclicas úteis para a inibição da função da g-pro-teína e para o tratamento de doenças proliferativas

Info

Publication number
BR9612203A
BR9612203A BR9612203A BR9612203A BR9612203A BR 9612203 A BR9612203 A BR 9612203A BR 9612203 A BR9612203 A BR 9612203A BR 9612203 A BR9612203 A BR 9612203A BR 9612203 A BR9612203 A BR 9612203A
Authority
BR
Brazil
Prior art keywords
theine
pro
inhibiting
treatment
function
Prior art date
Application number
BR9612203A
Other languages
English (en)
Inventor
Ronald J Doll
Joseph M Kelly
Alan K Mallams
F George Njoroge
Stacy W Remiszewski
Arthur G Tavaras
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR9612203A publication Critical patent/BR9612203A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
BR9612203A 1995-12-22 1996-12-19 Amidas tricíclicas úteis para a inibição da função da g-pro-teína e para o tratamento de doenças proliferativas BR9612203A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57795195A 1995-12-22 1995-12-22
US61576096A 1996-03-13 1996-03-13
PCT/US1996/019603 WO1997023478A1 (en) 1995-12-22 1996-12-19 Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
BR9612203A true BR9612203A (pt) 1999-07-13

Family

ID=27077386

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9612203A BR9612203A (pt) 1995-12-22 1996-12-19 Amidas tricíclicas úteis para a inibição da função da g-pro-teína e para o tratamento de doenças proliferativas

Country Status (24)

Country Link
EP (2) EP1380581A1 (pt)
JP (1) JP3193725B2 (pt)
KR (1) KR100295224B1 (pt)
CN (1) CN1326847C (pt)
AR (1) AR005152A1 (pt)
AT (1) ATE309238T1 (pt)
AU (1) AU730194B2 (pt)
BR (1) BR9612203A (pt)
CA (2) CA2240846C (pt)
CZ (1) CZ292791B6 (pt)
DE (1) DE69635424T2 (pt)
DK (1) DK1019392T3 (pt)
ES (1) ES2248826T3 (pt)
HK (1) HK1025571A1 (pt)
HU (1) HU228352B1 (pt)
IL (1) IL125062A (pt)
MX (1) MX9804956A (pt)
MY (1) MY119007A (pt)
NO (1) NO318232B1 (pt)
NZ (1) NZ326035A (pt)
PL (1) PL185597B1 (pt)
SK (1) SK86198A3 (pt)
TW (1) TW350844B (pt)
WO (1) WO1997023478A1 (pt)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
AU3732197A (en) * 1996-07-26 1998-02-20 Schering Corporation Method for preparing substituted 1-piperidinecarboxamide derivatives
US5925757A (en) * 1996-07-26 1999-07-20 Schering Corporation Method for preparing carboxamides
US6040305A (en) * 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
JP2001500505A (ja) * 1996-09-13 2001-01-16 シェーリング コーポレイション Ｆｐｔインヒビターとして有用な三環式化合物
US5958890A (en) * 1996-09-13 1999-09-28 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
IL128951A0 (en) * 1996-09-13 2000-02-17 Schering Corp Tricyclic compounds useful for inhibition of farnesyl protein transferase
US5945429A (en) * 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
PL332253A1 (en) * 1996-09-13 1999-08-30 Schering Corp Derivatives of subtituted benzocycloheptapyridine useful in inhibiting proteinous farnesil transferase
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
CZ84299A3 (cs) * 1996-09-13 1999-09-15 Schering Corporation Sloučeniny vhodné pro inhibici farnesylproteintransferasy
US5994364A (en) * 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
US5985879A (en) * 1996-09-13 1999-11-16 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
CZ84399A3 (cs) * 1996-09-13 1999-11-17 Schering Corporation Tricyklické inhibitory farnesyl protein transferázy
KR20000036111A (ko) * 1996-09-13 2000-06-26 둘락 노먼 씨. 파네실 단백질 트랜스페라제 억제제인 트리사이클릭 항종양성화합물
US6130229A (en) * 1996-10-09 2000-10-10 Schering Corporation Tricyclic compounds having activity as RAS-FPT inhibitors
US20030060434A1 (en) 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
NZ337283A (en) * 1997-02-18 2001-02-23 Canji Inc Use of a tumor suppressing nucleic acid which encodes wild type p53 or retinoblastoma proteins and paclitaxel derivative or a polyprenyl-protein transferase inhibitor for the treatment of neoplasms
US5998620A (en) * 1997-03-25 1999-12-07 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
US5760232A (en) * 1997-06-16 1998-06-02 Schering Corporation Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds
ZA985214B (en) * 1997-06-17 1999-01-07 Schering Corp Compounds useful for inhibition of farnesyl protein transferase
US6358968B1 (en) 1997-06-17 2002-03-19 Schering Corporation N-substituted urea inhibitors of farnesyl-protein transferase
US6051582A (en) * 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
AU8253598A (en) * 1997-06-17 1999-01-04 Schering Corporation Novel n-substituted urea inhibitors of farnesyl-protein transferase
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6689789B2 (en) 1997-06-17 2004-02-10 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6159984A (en) 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6218401B1 (en) 1997-06-17 2001-04-17 Schering Corporation Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
HUP0003215A2 (hu) * 1997-06-17 2001-06-28 Schering Corp. Farnezil-protein-transzferáz új fenil-szubsztituált triciklusos inhibitorai
US6225322B1 (en) 1997-06-17 2001-05-01 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5877177A (en) * 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6576639B1 (en) 1997-06-17 2003-06-10 Schering Corporation Compounds for the inhibition of farnesyl protein transferase
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
DK1041985T3 (da) * 1997-12-22 2006-06-19 Schering Corp Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme
CA2315685C (en) * 1997-12-22 2008-02-05 Schering Corporation Molecular dispersion composition with enhanced bioavailability
DE69905891T2 (de) * 1998-07-02 2003-11-20 Schering Corp Verfahren zur herstellung von (8-chloro-3,10-dibromo-6,11-dihydro-5h-benzo[5,6] cyclohepta[1,2-b]pyridin-11-yl)-1-piperidin
US6706883B1 (en) * 1998-07-02 2004-03-16 Schering Corporation Process for producing (8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-B]pyridin-11-YL)-1-piperdine
US6535820B1 (en) * 1998-08-28 2003-03-18 Schering Corporation Crystalline farnesyl protein transferase compositions and methods for use
US6372909B1 (en) 1998-11-20 2002-04-16 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
US6307048B1 (en) 1998-11-20 2001-10-23 Schering Corporation Enantioselective alkylation of tricyclic compounds
PT1131313E (pt) * 1998-11-20 2003-06-30 Schering Corp Alquilacao enantiosselectiva de compostos triciclicos
AU3790200A (en) 1998-11-20 2000-06-13 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
CN1198816C (zh) * 2000-11-29 2005-04-27 先灵公司 新的法尼基蛋白转移酶抑制剂
AU2003272767A1 (en) * 2002-09-30 2004-04-23 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
CA2501292A1 (en) * 2002-10-03 2004-04-15 Schering Corporation Enantioselective alkylation of tricyclic compounds
TW200510384A (en) 2003-08-07 2005-03-16 Schering Corp Novel farnesyl protein transferase inhibitors as antitumor agents
US7417026B2 (en) 2003-08-13 2008-08-26 Children's Hospital Medical Center Mobilization of hematopoietic cells
EP1732549A4 (en) * 2004-03-18 2009-11-11 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
WO2008054598A2 (en) * 2006-09-29 2008-05-08 Schering Corporation Panel of biomarkers for prediction of fti efficacy
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
JP5330274B2 (ja) 2007-03-01 2013-10-30 ノバルティス アーゲー Ｐｉｍキナーゼ阻害剤およびその使用方法
WO2008144062A1 (en) 2007-05-21 2008-11-27 Novartis Ag Csf-1r inhibitors, compositions, and methods of use
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
WO2009145852A1 (en) * 2008-04-17 2009-12-03 Concert Pharmaceuticals, Inc. Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof
EP2358370A2 (en) * 2008-11-13 2011-08-24 Link Medicine Corporation Treatment of proteinopathies using a farnesyl transferase inhibitor
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
KR101485645B1 (ko) 2009-10-14 2015-01-22 머크 샤프 앤드 돔 코포레이션 ｐ53 활성을 증가시키는 치환된 피페리딘 및 그의 용도
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2547661A2 (en) 2010-03-16 2013-01-23 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 ***-1受体抑制剂
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
LT2925888T (lt) 2012-11-28 2018-01-10 Merck Sharp & Dohme Corp. Vėžio gydymo kompozicijos ir būdai
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
KR20160072352A (ko) 2014-12-12 2016-06-23 동보씨엠텍산업(주) 저위투입구 믹서로더
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP2018517673A (ja) * 2015-04-21 2018-07-05 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ロナファルニブおよびリトナビルを含む医薬組成物
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US20210277009A1 (en) 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20210309688A1 (en) 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
DK0723538T3 (da) * 1993-10-15 2002-03-18 Schering Corp Tricykliske carbamatforbindelser, der er nyttige til inhibition af funktion af G-protein og til behandling af proliferative sygdomme
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
CN1326847C (zh) 2007-07-18
CZ193898A3 (cs) 1998-10-14
EP1019392B1 (en) 2005-11-09
AU1331197A (en) 1997-07-17
HK1025571A1 (en) 2000-11-17
PL327312A1 (en) 1998-12-07
ATE309238T1 (de) 2005-11-15
IL125062A0 (en) 1999-01-26
NO982878D0 (no) 1998-06-19
TW350844B (en) 1999-01-21
JP3193725B2 (ja) 2001-07-30
NO982878L (no) 1998-08-24
NO318232B1 (no) 2005-02-21
CZ292791B6 (cs) 2003-12-17
WO1997023478A1 (en) 1997-07-03
KR19990076655A (ko) 1999-10-15
CA2240846C (en) 2002-07-16
MX9804956A (es) 1998-09-30
HUP9903705A2 (hu) 2000-05-28
NZ326035A (en) 2000-01-28
CA2358394A1 (en) 1997-07-03
AU730194B2 (en) 2001-03-01
KR100295224B1 (ko) 2001-09-17
CA2240846A1 (en) 1997-07-03
ES2248826T3 (es) 2006-03-16
IL125062A (en) 2003-11-23
CN1209127A (zh) 1999-02-24
DK1019392T3 (da) 2006-03-20
EP1019392A1 (en) 2000-07-19
CA2358394C (en) 2006-05-02
EP1380581A1 (en) 2004-01-14
PL185597B1 (pl) 2003-06-30
AR005152A1 (es) 1999-04-14
DE69635424T2 (de) 2006-08-03
SK86198A3 (en) 1999-02-11
JPH11501671A (ja) 1999-02-09
HUP9903705A3 (en) 2002-04-29
HU228352B1 (en) 2013-03-28
DE69635424D1 (de) 2005-12-15
MY119007A (en) 2005-03-31

Similar Documents

Publication Publication Date Title
BR9612203A (pt) Amidas tricíclicas úteis para a inibição da função da g-pro-teína e para o tratamento de doenças proliferativas
BR9604787A (pt) Compostos tricíclicos utilizáveis para inibição de função de proteína g e para tratamento de doenças proliferativas
DE69626104T2 (de) Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und zur behandlung von proliferativen erkrankungen
IL117603A0 (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117604A0 (en) Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117602A0 (en) Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
BR9508886A (pt) Compostos e métodos para o tratamento de câncer
IL124855A (en) 5-amino-3-cyano-4-ethylsulfinyl-1-phenyl-pyrazole compounds and their use as pesticides
AR002336A1 (es) Proceso para el tratamiento de gas efluente
NO20003065L (no) Kombinasjon for effektiv behandling av impotens
BR9610733A (pt) Composto processos para a preparação do mesmo e para o tratamento de um mamífero composição farmacêutica e utilização de um composto
BR9606426A (pt) Procedimento e dispositivo para distribuição de correspondência
IL117797A0 (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
DE9319185U1 (de) Leuchten und Blenden dafür
EE03437B1 (et) Benseenamiidid neurodegeneratiivsete haiguste ravimiseks
BR9606925A (pt) Utilização de compostos e processo para o tratamento e profilaxia da obesidade
BR9709964A (pt) Derivados de catecol aplicação de derivados de catecol e medicamento
DE69713442D1 (de) Thioürazil-Derivate und diese enthaltende Metall-Oberflächebehandlungsmittel
NO962385D0 (no) Terapeutiske amider
GB9523066D0 (en) Compounds and their therapeutic use
ZA9610735B (en) Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
AU2520395A (en) Inverse skewing of the lymphocyte repertoire for therapy and prevention of disease
KR940002718U (ko) 치질예방 및 치료기
KR960027271U (ko) 이탈 및 부상방지용 스페이서
KR940018945U (ko) 치질치료 및 예방용 좌욕조

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time